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ABSTRACT 
Mutations in nucleophosmin NPM1 are the most frequent acquired molecular 
abnormalities in acute myeloid leukemia (AML). We determined the NPM1 
mutation status in a clinically and molecularly well-characterized patient cohort 
of 275 patients with newly diagnosed AML by denaturing high performance 
liquid chromatography (dHPLC). We show that NPM1 mutations are 
significantly underrepresented in patients younger than 35yr. NPM1 mutations 
positively correlate with AML with high white blood cell counts, normal 
karyotypes and FLT3 internal tandem duplication (ITD) mutations. NPM1 
mutations associate inversely with the occurrence of CEBPA- and N-RAS 
mutations. With respect to gene expression profiling, we show that AML cases 
with an NPM1 mutation cluster in specific subtypes of AML with previously 
established gene expression signatures, are highly associated with a 
homeobox gene-specific expression signature and can be predicted with high 
accuracy. We demonstrate that patients with intermediate cytogenetic risk 
AML without FLT3 ITD mutations but with NPM1 mutations have a 
significantly better OS and EFS than those without NPM1 mutations. Finally, 
in multivariable analysis NPM1 mutations express independent favorable 
prognostic value with regard to overall-, event free- and disease free survival. 
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INTRODUCTION 
Acute myeloid leukemia (AML) is a heterogeneous disease with diverse 
genetic abnormalities and variable responsiveness to therapy. Cytogenetic 
analyses and molecular analyses are currently used to risk-stratify AML. For 
instance, the translocations inv(16), t(8;21), and t(15;17) herald a favorable 
prognosis, whereas certain other cytogenetic aberrations indicate leukemia 
with intermediate or high risk of relapse 
1-5. Nevertheless, the classification of 
AML on the basis of karyotyping is still far from satisfactory. In recent years 
extended molecular analyses have yielded novel molecular markers important 
for proper diagnostics of AML. The ITD in the fms-like tyrosine kinase-3 gene 
(FLT3) 
6,7, partial tandem duplication (PTD) 
8,9 of the mixed lineage leukemia 
gene (MLL) and increased expression of the transcription factor EVI1 
10, are 
indicative of poor prognosis. In contrast, mutations in the transcription factor 
CEBPA have been associated with a favorable response to therapy 
11,12. A 
recent study showed mutations in exon 12 of the gene encoding 
nucleophosmin  NPM1 in approximately 35% of cases of de novo AML 
13. 
Mutations of NPM1 were found to be mutually exclusive with certain common 
recurrent chromosomal aberrations, and are predominantly seen in AML with 
normal karyotypes and FLT3 ITD mutations.  
NPM1 is predominantly localized in the nucleolus and is thought to function as 
a molecular chaperone of proteins, facilitating the transport of ribosomal 
proteins through the nuclear membrane 
14-16. Disruption of NPM1, either by 
chromosomal translocation or by mutation, results in the cytoplasmic 
dislocation of NPM1. The high frequency of NPM1 mutations in AML with 
normal karyotypes and the observation that cytoplasmic NPM1 cannot exert 
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its normal functions as binding partner and transporter protein lead to the 
notion that NPM1 mutation may be an early event in leukemogenesis.  
An important role for NPM1 in leukemias and lymphomas has been proposed 
previously. NPM1 has been found to be part of several fusion proteins, which 
are formed as a result of chromosomal translocation and in which only the 
NPM1 N-terminal region is conserved. A t(2;5)(p23;q35) chromosomal 
translocation occurs in approximately 8% of non-Hodgkin lymphomas in 
children and young adults and results in the chimeric fusion of NPM1 to ALK 
17. In rare cases of acute promyelocytic leukemia (APL), characterized by 
chromosomal translocations that disrupt the gene encoding the retinoic acid 
receptor (RARA), fusion of NPM1 to RARA was shown 
18. A t(3;5)(q25.1;q34) 
chromosomal translocation, infrequently seen in myelodysplastic syndrome 
and AML gives rise to a fusion transcript of NPM1 and MLF1 
19.  
Gene expression profiling is a powerful way to comprehensively classify 
individuals with AML and to further resolving the heterogenous nature of AML 
20. Using this technique, new prognostically relevant AML subtypes have been 
identified, while the presence of recurrent chromosomal abnormalities such as 
inv(16), t(15;17) and t(8;21) as well as other molecular aberrations, e.g., C- 
and N-terminal mutations in CEBPA, could be predicted with high accuracy by 
unique expression patterns 
21-23. In recent study, novel subtypes of AML have 
also been defined based on gene expression profiling, however, the common 
molecular abnormalities in these AML subtypes are largely unknown 
21. Since 
NPM1 is mutated in approximately one third of AML patients, this molecular 
abnormality may drive the clustering of these AML subtypes. The effect of 
mutant NPM1 has been studied using gene expression profiling and revealed 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From Verhaak et al.  NPM1 mutations in AML
  
  5
a distinctive signature of NPM1 mutations 
24. Amongst players in this 
signature were several homeodomain-containing family members of HOX 
transcription factors and CD34, both observations being indicative of 
hematopoietic development 
24. However, it is currently not known whether 
NPM1 mutations are predictable on the basis of a gene expression signature. 
Cytoplasmic NPM1 has been positively associated with remission rate 
13, 
however, the relation of mutant NPM1 with survival outcome parameters 
remains to be elucidated. 
We have studied a well-characterized cohort of 275 cases of de novo AML for 
the presence of a NPM1 mutations to (I) validate dHPLC as a rapid approach 
to determine NPM1 mutations, (II) investigate the relation of NPM1 mutations 
with regard to clinical parameters, cytogenetics and various molecular 
abnormalities, (III) determine the relation of NPM1 mutations in subtypes of 
AML, recently identified by gene expression profiling 
21, (IV) derive NPM1 
mutation specific and predictive gene expression signatures and (V) 
determine the prognostic value of mutated NPM1. 
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PATIENTS AND METHODS 
Patients and cell samples 
Patients had a diagnosis of primary AML, confirmed by cytological 
examination of blood and bone marrow (median age 44 (range 15-78), 
median bone marrow blast count 65 percent (range 0 (for APL) -98), median 
white blood cell (WBC) count 32 (x10
9/l) (range 0.3-263)). All patients had 
been treated according to the HOVON (Dutch-Belgian Hematology-Oncology 
Co-operative group) protocols)
25-27. After informed consent, bone marrow 
aspirates or peripheral blood samples were taken at diagnosis. Blasts and 
mononuclear cells were purified by Ficoll-Hypaque (Nygaard, Oslo, Norway) 
centrifugation and cryopreserved. The AML samples contained 80-100 
percent blast cells after thawing, regardless of the blast count at diagnosis.  
 
PCR, WAVE and sequence analyses 
RNA isolation and cDNA synthesis were performed as described 
21,28. cDNA 
prepared from 50ng of RNA was used for all PCR amplifications. NPM1 
mutations in exon 12 were determined by cDNA amplification using the 
primers NPM1-FOR 5'-CTTCCGGATGACTGACCAAGAG-3' and primer 
NPM1-REV 5'-CCTGGACAACATTTATCAAACACG-3' (25mM dNTP, 15 pmol 
primers, 2mM MgCl2, Taq polymerase and 10xbuffer (Invitrogen Life 
Technologies, Breda, The Netherlands)). Cycling conditions for NPM1 
mutation detection were as follows: 1 cycle 5' 94
0C, 30 cycles 1' 94
0C, 1' 
58
0C, 1' 72
0C, and 1 cycle 7' 72
0C. PCR products were subsequently 
subjected to dHPLC using a Transgenomics (Omahah, NE) WAVE dHPLC 
system 
29. Samples were run at 56
0C and 58
0C. The exact NPM1 mutant 
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sequence was confirmed for all samples showing an abnormal dHPLC profile. 
PCR products were purified using the Multiscreen-PCR 96-well system 
(Millipore, Bedford, MA) followed by direct sequencing with NPM1-REV using 
an ABI-PRISM3100 genetic analyzer (Applied Biosytems, Foster City, CA).   
Sequence analyses for mutations in FLT3 (ITD and tyrosine kinase domain 
mutation (TKD)), N-RAS, K-RAS and CEBPA performed as described 
previously.
12,30,31.  
 
Gene expression profiling and unsupervised cluster analyses  
285 AML cases were analyzed using Affymetrix HGU133A GeneChips 
21. 
Unsupervised cluster analysis on the basis of the gene expression profiles of 
the 285 cases of AML was performed using the Correlation Visualization tool 
of Omniviz  (Maynard, MA (version 3.6)) 
21. The Pearson’s correlation values 
calculated in Omniviz were subsequently imported into the MicroArray Data 
Explorer (MADEx), which was developed in our laboratory. MADEx was used 
to visualize the relations between the Omniviz unsupervised clustering results 
and other parameters, such as clinical and molecular characteristics of the 
AML patients (Figure 1).  MADEx is a database system that stores, mines and 
visualizes microarray data in a secure and scalable manner.  
 
Significance Analysis of Microarrays (SAM)  
All supervised analyses were performed using Significance Analysis of 
Microarrays (SAM) (version 1.21) 
32. A threshold was set for a minimum 
change in expression of at least 1.5-fold. A false discovery rate of 0.01 was 
used to select the differentially expressed genes.  
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Prediction Analysis of Microarrays (PAM)  
All supervised class prediction analyses were performed by applying 
Prediction Analysis of Microarrays (PAM) (version 2.0) 
33. The gene signature 
was selected based on the smallest prediction error in the training set and 
was subsequently tested using the test set. The positive predictive value was 
calculated with (true positives/(true positives + false positives)). 
 
Statistical analyses of survival 
Cytogenetic abnormalities were categorized in 3 cytogenetic groups for 
statistical analyses. Patients with inv(16)/t(16;16), t(8;21), and t(15;17) 
abnormalities were considered as being in the favorable-risk category. The 
unfavorable-risk category was defined by the presence of -5/del(5q), -
7del(7q), t(6;9), t(9;22), 3q26 abnormality or complex karyotype (more than 3 
abnormalities). All other patients were classified as intermediate risk. 
Statistical analyses were performed with Stata Statistical Software, Release 
7.0 (Stata, College Station, TX). Actuarial probabilities of overall survival (OS) 
(with failure defined as death due to any cause) and event-free survival (EFS) 
(with failure defined as not achieving complete remission (set at day 1), 
relapse, or death in first complete remission) were estimated by the method of 
Kaplan and Meier.  The Cox proportional hazards model was applied to 
determine the association of NPM1 mutation with OS, EFS and disease-free 
survival (DFS), without and with adjustment for other factors such as 
cytogenetic risk, age, white blood cell count and FLT3 ITD. All tests were 2-
sided, and a P of less than .05 was considered statistically significant. 
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RESULTS 
Different NPM1 variant mutations in AML  
The presence of NPM1 mutations in 275 cases of primary AML was rapidly 
and reliably detected by dHPLC WAVE. Nucleotide sequencing was 
performed on those cases with an abnormal dHPLC profile (Table 1). Each 
NPM1 mutation variant reveals a specific dHPLC WAVE profile. Thus, each 
type of NPM1 mutation could be predicted on the basis of a specific dHPLC 
WAVE profile.  
In addition, three novel NPM1 mutant variants were identified (NPM1 mutants 
I to K (Table 1)). These rare variants have comparable 4-base pair insertions, 
like  NPM1 variant mutations A to D 
13, resulting in a frame shift and 
replacement of the 7 C-terminal amino acids of the NPM1 protein by 11 
different residues (Table 1). 
 
NPM1 mutations in relation to clinical and molecular features in AML  
The NPM1 mutation frequencies of the 275 cases of primary AML with regard 
to clinical parameters, morphology, cytogenetics and molecular characteristics 
are shown in Table 2. NPM1 mutations are significantly less frequently 
present in patients of younger age (<35 yr, p<0.001). The mean age of 
patients with AML and NPM1 mutations is 47.3 (±10.7), whereas the mean 
age of patients with AML and wild-type NPM1 is 39,7 (±13.3). NPM1 
mutations are seen in AML FAB subtypes M1 to M6, but are absent in AML 
FAB M0. The mutations are relatively frequently found in AML FAB M5 as well 
as in all three cases of AML FAB M6. In AML with recurrent translocations, 
i.e., t(8;21), inv(16) and t(15;17), no NPM1 mutations were demonstrated. In 
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cases with various other cytogenetic abnormalities, mutations in NPM1 were 
also rare. As a result, there appears a positive correlation between NPM1 
mutations and AML with normal karyotypes (p<0.001). The analysis of NPM1 
mutations reveals interesting relationships with particular common molecular 
abnormalities. The presence of NPM1 mutations significantly correlates with 
the presence of FLT3 ITD mutations (p<0.001). A correlation between NPM1 
mutations and FLT3 TKD mutations is not apparent. AML with N-RAS 
mutations showed a significantly lower percentage of NPM1 mutations 
(p=0.024). Among 5 of 8 cases of AML with NPM1 mutations K-RAS 
mutations were found. No mutations in NPM1 were found in cases of AML 
with CEBPA mutations (p=0.001).  
 
NPM1 mutations occur within specific AML subtypes defined by gene 
expression profiling 
Of the cohort of 285 cases of primary AML which had previously been profiled 
using the Affymetrix HGU133 GeneChip 
21 and for which 16 distinct   
expression signatures had been defined following unsupervised cluster 
analyses, we have now examined 275 cases for the presence of NPM1 
mutations. Among these pre-established signatures, the AML cases with 
NPM1 mutations aggregate within particular clusters (Figure 1). The majority 
of AML cases in clusters #2, #3, #5 and #7 carry NPM1 mutations. As a 
matter of fact, all cases of AML of clusters #6 (100% FLT3 ITD) and #11 (78% 
normal karyotypes) carried mutations in NPM1. Although, clusters #7 and #8 
have comparable expression profiles (Figure 1), 13 out of the 18 AML cases 
in cluster #7 (72%) and only 1 of 12 cases of cluster #8 (8%) reveal NPM1 
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mutations. The clusters merely consisting of AML with inv(16) (#9), t(15;17) 
(#12) or t(8;21) (#13) as well as the clusters predominantly containing cases 
with CEBPA mutations (#4 and #15) all lack NPM1 mutations. The subset of 
AML patients in cluster #10, with adverse prognosis and an expression profile 
comparable to CD34-positive cells 
21, did not present with NPM1 mutations.  
Falini and colleagues 
13 had shown a negative correlation between the 
presence of NPM1 mutations and CD34 expression levels. In fact, by plotting 
the CD34 mRNA expression levels of the 285 AML cases, as determined by 
the GeneChip analyses, along the NPM1 mutation status (Figure 1), a 
distinguishable association of CD34 mRNA expression and NPM1 mutation is 
apparent, i.e., CD34 mRNA expression is low or absent in cases of AML with 
NPM1 mutations, while CD34 mRNA levels are high in AML cases without 
NPM1 mutations. 
 
HOX gene-specific gene expression signature of NPM1 mutant cases 
To identify genes with significant differential expression between primary AML 
samples with NPM1 mutations (n=95) and samples without NPM1 mutations 
(n=180) the SAM algorithm was used 
32. A fold change threshold of 1.5 for 
upregulation of gene expression and 0.667 for downregulation of gene 
expression was applied. With a False Discovery Rate (FDR) of 0.01, 569 
probe sets representing 440 unique genes, were identified as being 
significantly differentially expressed (Supplementary Figure 1 and Table 1). 
The identity of the Top-50 genes, in some cases represented by multiple 
probe sets, are depicted in Table 3.  
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From Verhaak et al.  NPM1 mutations in AML
  
  12
A dominant homeobox (HOX) gene-specific signature is strongly associated 
with AML carrying an NPM1 mutation. Moreover, the expression of members 
of the HOXA- and HOXB-gene families, but also the HOX gene-related TALE 
genes, PBX3 and MEIS1 are increased. In contrast, the CD34 gene is the 
strongest significantly down regulated gene with regard to NPM1 mutation in 
the AML patient cohort.  
 
NPM1 mutant cases are predicted with high accuracy based on their 
gene expression signature  
NPM1 mutation prediction analyses were performed using the PAM algorithm 
33. All 275 primary AML samples were randomly assigned to a training set, 
consisting of 122 samples without NPM1 mutations and 62 samples with 
NPM1 mutations, and a validation series, consisting of 58 samples lacking the 
NPM1 mutation and 33 samples with mutations in NPM1.  Cross validation to 
predict the mutation status of NPM1 on the training set resulted in 100% 
correct predictions on presence of mutation (sensitivity) and 80.3% correct 
predictions on absence of mutation (specificity) (Table 4). Prediction of an 
independent validation set also resulted in 100% correct prediction of 
presence of mutation and 82.7% correct prediction on absence of mutation. 
The positive predictive value in this cohort is 72% in the training set and 74% 
overall.  As expected, the genes included in the PAM gene signature were 
among the most significant differentially expressed genes as determined by 
SAM, thereby validating both algorithms. Of note, NPM1 mRNA expression 
did not correlate with mutation status (Figure 2). The NPM1 mutant AML 
cases have a distinct signature with regard to the 18 selected genes (Figure 
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2) and are therefore predicted with high accuracy (Table 4). However, these 
18 genes seem to be expressed at comparable levels in a subset of AML 
cases with wild type NPM1 (Figure 2).  
 
NPM1 mutation is an independent favorable prognostic marker  
To investigate the prognostic value of NPM1 mutation 252 AML patients with 
long term follow up following therapy completion were included for survival 
analysis. The EFS, OS and probability of relapse at 60 months for the AML 
patients with or without NPM1 mutations were similar (Figures 3A and 3B). 
Likewise, among the subgroup with cytogenetics of intermediate prognostic 
risk EFS, OS and probability of relapse at 60 months were not different either 
(Figures 3C and 3D), although there appears a trend for more favorable 
outcome for patients with AML with NPM1 mutations. Since NPM1 mutations 
are significantly associated with both normal karyotype and presence of a 
FLT3 ITD (Table 2), we wished to investigate the prognostic value of NPM1 
mutations within the intermediate cytogenetic risk group in relation to FLT3 
ITD status. Patients in the intermediate cytogenetic risk group without FLT3 
ITD mutations but with NPM1 mutations have a significantly better OS and 
EFS than those without NPM1 mutations (p=0.05) (Figures 4A and C). In 
intermediate cytogenetic risk AML with FLT3 ITD mutations NPM1 mutations 
do not significantly distinguish prognosis (Figures 4B and D). 
NPM1 mutations are asynchronously associated with particular karyotypes 
and molecular abnormalities that might express additional positive or negative 
prognostic value and therefore might obscure the prognostic significance of 
NPM1 mutations (Table 2 and Figure 1). Therefore we investigated the 
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prognostic value of NPM1  mutations in both univariable and multivariable 
analyses. Univariable and multivariable Cox regression analysis were applied 
to assess the prognostic significance of NPM1 mutation, cytogenetic risk 
class, WBC below or above 20, age and FLT3 ITD mutation for OS, DFS and 
EFS (Table 5).  In univariable analyses NPM1 mutation showed no statistical 
significance with respect to the endpoints. However, in multivariable analyses 
mutated NPM1 was significantly associated with a much lower hazard ratio, 
which was statistically significant for all endpoints (EFS: HR = 0.59, p = 0.005; 
DFS: HR = 0.52, p = 0.003 and OS: HR = 0.49, p = 0.0003). Mutant NPM1 
appeared as independent prognostic marker in addition to cytogenetic risk, 
age and FLT3 ITD mutations. 
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DISCUSSION  
Recently, we established a comprehensive classification of AML based on 
whole-genome expression profiling 
21. In this classification several clusters of 
AML signatures correlated with distinct (cyto)genetic abnormalities, such as 
t(8;21), t(15;17), inv(16) and C- and N-terminal mutations in CEBPA. 
However, the common underlying molecular abnormality for the other 
subtypes of AML was unknown. In the present study we show that two 
clusters consist entirely of AML cases with NPM1 mutations, i.e., clusters #6 
and #11, whereas clusters #2, #3, #5 and #7 predominantly include patients 
with  NPM1 mutations. Thus, we identify mutant NPM1 as a common 
molecular abnormality in these subtypes of AML. 
Falini and colleagues 
13 have shown that mutations in NPM1 are present in 
35% of patients with AML. In this study, we confirm that NPM1 mutations are 
frequently present in AML, i.e., in 35% of all cases. NPM1 mutant is less 
frequently represented in patients with AML of age less than 35 yr. This 
seems consistent with the tendency of the NPM1 mutation to be more 
frequently present in older children with AML 
34. Furthermore, NPM1 
mutations are significantly associated with AML with high WBC.  
We detected the various mutation variants of NPM1 at similar frequencies as 
was described recently 
13, and also identified three novel mutant variants. 
These novel variants carry, like the other NPM1 mutant variants in our study, 
an insertion of 4 bp, resulting in a protein with an altered C-terminus (Table 1). 
Falini and colleagues 
13 suggested that the disruption of one of the two C-
terminal tryptophan residues and the last five residues, i.e., VSLRK, are 
important for NPM1 mutant function. Our study suggests that the final 9 
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aminoacids, i.e., AVEEVSLRK, may in general be required for mutant NPM1 
function. 
NPM1 mutations often coincide with mutations in FLT3, in particular with the 
ITD-type mutations. Our data may suggest an association of mutations in K-
RAS and NPM1, but the study has limited power because of the small number 
of mutant K-RAS AML. In contrast, mutations in N-RAS were not associated 
with mutant NPM1, since N-RAS mutations are found in AML with inv(16) 
21,30, 
a subclass of AML which lacks NPM1 mutations. In addition, we did not find 
NPM1 mutations in clusters of AML patients, previously identified by gene 
expression profiling 
21, characterized by C- and N-terminal mutations in 
CEBPA. These observations might perhaps suggest that constitutive active 
FLT3 or K-RAS provide the proliferative signal, whereas mutant NPM1 might 
serve to impair differentiation in the multistep pathogenesis model of AML 
35. 
It is of note that, the discriminative genes identified by SAM and PAM 
revealed a strong HOX- and TALE- gene-specific signature associated with 
AML cases with mutant NPM1, as was published very recently 
24. Thus, 
although CD34 has generally been used as marker for immature 
hematopoietic progenitor cells, the NPM1 mutant CD34-negative cells display 
a molecular signature similar to that of hematopoietic stem cells (HSC). 
Recent studies have shown that CD34-negative HSCs exist as well 
36,37. 
These CD34-negative cells also posses HSC-specific characteristics, 
including the ability for hematopoietic engraftment 
36,37. This brings up the 
question whether the NPM1 mutant AML cells in fact represent a more 
primitive population of HSCs with a HOX-gene signature.  
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The sharp distinction between CD34-positivity and NPM1 mutations in AML 
cases based on the HOX-gene signature is notable since 22 of the 39 HOX 
genes are expressed in human CD34-positive cells, whereas during normal 
differentiation  HOX gene expression declines 
38. Extensive studies have 
demonstrated for a number of HOX-genes that sustained overexpression in 
murine bone marrow results in perturbations in the stem cell pools, and co-
expression of certain HOX-gene family members with their protein binding 
partner, such as MEIS1, results in leukemia 
38. Thus, in AML with NPM1 
mutations the hematopoietic progenitor cells may have arrested at a 
differentiation stage with endogenous co-expression of the HOX-genes, i.e., 
HOXA5, -A9, -A10, -B2, -B3, -B5 and -B6, and their TALE partner genes, i.e., 
MEIS1 and PBX3, or as a result of the increased expression of these genes. 
SAM and PAM analyses were highly concordant for the genes identified with 
differential expression between AML with mutant and AML with wild type 
NPM1, where, in both cases, CD34 was the most discriminating gene, 
downregulated in NPM1 mutants. Patients harboring an NPM1 mutation can 
be predicted with high accuracy, however, a subset of patients with wild type 
NPM1 is wrongly predicted. Interestingly, within this subgroup the percentage 
of patients with 11q23 abnormalities is significantly increased. In fact, this may 
not be surprising since MLL has been implicated as a HOX gene regulator 
39 
and selective expression of HOX genes in ALL cases with mutant MLL has 
been shown 
40.  
By univariate analyses we show that there is a tendency that the presence of 
an  NPM1 mutation, and concomitant low CD34 mRNA expression, is a 
favorable marker for clinical outcome (Figure 3). This is in agreement with 
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CD34 expression as an indicator for poor response to induction therapy 
41-43. 
In addition, we demonstrate by multivariate analyses that NPM1 mutations are 
a strong independent favorable predictive marker for EFS, DFS and OS in 
AML. The finding that the effect of NPM1 mutation is much more pronounced 
in multivariable than in univariable analyses can be explained by the strong 
correlation between NPM1 and FLT3 ITD mutations, and additionally by the 
association with high WBC and age. NPM1 mutations are more frequently 
present in AML patients with FLT3 ITD, high WBC and older age. These 
factors are unfavorable determinants of prognosis 
44, while NPM1 mutation 
seems to express a favorable prognostic impact. This implies that in 
univariable analysis the positive effect of NPM1 mutations, as measured by 
the method of Kaplan-Meier or by the HR, is less pronounced, since the 
adverse effects of FLT3 ITD, high WBC and age might mask this effect. In 
fact, NPM1 mutations distinguish a favorable subgroup among intermediate 
cytogenetic risk FLT3 ITD negative AML, that shows comparatively better OS 
and EFS (Figure 4). In addition, we note that in the multivariable analyses the 
effect of NPM1 mutations is more pronounced than is apparent in the 
univariable analyses. This is not only true for NPM1 mutations, but also for the 
independent prognostic effect of FLT3 ITD mutations, age and cytogenetic 
risk (Table 5). 
The data presented here demonstrate that the frequent C-terminal insertion 
mutations in NPM1 correlate with favorable outcome for patients with AML. 
Since NPM1 mutations are predominantly found in patients with standard risk 
AML, determination of the NPM1 mutation status, in combination with other 
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prognostically relevant markers, will be useful for further risk stratification of 
adult patients with de novo AML. 
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LEGENDS TO FIGURES 
Figure 1: Adapted Omniviz Correlation View of 285 AML patients (2856 
probe sets) 
21. The Correlation View displays pair-wise correlations between 
AML patients. The cells in the visualization are colored by Pearson's 
correlation coefficient values with deeper colors indicating higher positive (red) 
or negative (blue) correlations. The scale bar indicates maximum positive 
correlation (red) towards maximum negative correlation (blue). The 16 
clusters identified in the cohort of 285 AML patients on the basis of the 
Correlation View are indicated (1 to 16) 
21. Clinical and molecular data are 
depicted in the columns along the original diagonal of the Correlation View 
21. 
FAB classification and karyotype based on cytogenetics are depicted in the 
first two columns (FAB M0-red, M1-green, M2-purple, M3-orange, M4-yellow, 
M5-blue, M6-grey; karyotype: normal-green, inv(16)-yellow, t(8;21)-purple, 
t(15;17)-orange, 11q23 abnormalities-blue, 7(q) abnormalities-red,  +8-pink, 
complex-black, other-gray). FLT3 ITD and NPM1 mutations are depicted in 
the same set of columns (red bar: positive and green bar: negative). The 
expression levels of CD34 (probe set: 209543_s_at) in the 285 AML patients 
are plotted in the last column (bars are proportional to the level of expression). 
The percentages of the most common (>40 percent) abnormalities, NPM1 
mutations as well as normal karyotypes (NN) for each cluster are indicated. 
 
Figure 2: The most predictive molecular signature with regard to NPM1 
mutation in AML assessed with 22 probe sets representing 18 unique 
genes. The levels of expression of the probe sets in the 275 cases of AML 
are depicted (scale bar indicates an increase (red) or a decrease (green) in 
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the level of expression of at least 4 relative to the geometric mean) 
21. The 
three probe sets representing the NPM1 gene are also depicted. 
 
Figure 3: Survival analyses of AML patients with and without NPM1 
mutations. Kaplan-Meier estimates of overall survival (A) and event free 
survival (B) among patients with AML, overall survival (C) and event free 
survival (D) among patients with AML with intermediate risk karyotypes.  
 
Figure 4: Survival analyses of intermediate cytogenetic risk AML 
patients with and without FLT3 ITD and/or NPM1 mutations. Kaplan-Meier 
estimates of overall survival (A and B) and event free survival (C and D) for 
patients with intermediate risk AML and FLT3 ITD mutations (FLT3 ITD+ (B 
and D)) versus those with intermediate risk AML without FLT3 ITD mutations 
(FLT3 ITD- (A and C)). 
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TABLES 
Table 1. NPM1 mutation frequencies in 275 cases of de novo AML. 
 
NPM1 variant  Nucleotide sequence             Protein sequence**      # NPM1  percentage (%, n=275) 
    (inserted nucleotides underlined and italicized)               mutants 
 
WT   GATCTCTG....GCAGT....GGAGGAAGTCTCTTTAAGAAAATAG  -DLWQWRKSL 
Mutant A  GATCTCTGTCTGGCAGT....GGAGGAAGTCTCTTTAAGAAAATAG  -DLCLAVEEVSLRK      72    26 
Mutant B  GATCTCTGCATGGCAGT....GGAGGAAGTCTCTTTAAGAAAATAG  -DLCMAVEEVSLRK      12    4 
Mutant D  GATCTCTGCCTGGCAGT....GGAGGAAGTCTCTTTAAGAAAATAG  -DLCLAVEEVSLRK      4     1 
 
Mutant I*  GATCTCTGCAGAGCAGT....GGAGGAAGTCTCTTTAAGAAAATAG  -DLCRAVEEVSLRK      1     <1 
Mutant J*  GATCTCTGCTTGGCAGT....GGAGGAAGTCTCTTTAAGAAAATAG  -DLCLAVEEVSLRK      1     <1 
Mutant K*  GATCTCTGTATGGCAGT....GGAGGAAGTCTCTTTAAGAAAATAG  -DLCMAVEEVSLRK      1     <1 
 
ND***                      4    1 
 
Total                      95  35 
 
 
*NPM1 mutant G,H and I are novel variants identified in addition to the 6 known NPM1 variants 
13  
**The C-terminal tryptophane residues (W) are underlined for wild-type (WT) NPM1 
***ND: not determined
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Table 2. NPM1 mutation frequencies in relation to clinical parameters, morphology, 
cytogenetics and molecular characteristics of the 275 patients with de novo AML  
 
     #    #   NPM1    percentage  p-value 
mutants   (%)    
Male      135   40   30   0.100 
Female      140   55   39 
 
Age groups     Younger than 35    74    11    15               <0.001 
                        35-60    169    69    41   
                        60 and older    32    15    47 
 
WBC  (10e9/l)  <=  20    113   28   25   0.0044 
  >20    157   66   42    
 ND    5    1 
 
FAB                  M0    6    0    0    ND 
                        M1    62    21    34    1.000 
                         M2    63    18    29    0.296 
                         M3    17    1    6    0.008 
                         M4    49    15    31    0.062 
                         M5    65    32    49    0.007 
                         M6    3    3    100    ND 
    ND    10   5    
 
Cytogenetic abnormalities* 
  t(15;17)    16   0   0   0.002 
  t(8;21)        21    0    0               <0.001 
  inv(16)/t(16;16)    17   0   0   0.001 
  + 8       2 4    5    2 1    N D  
  +11     5   0   0   ND 
  +21     1   1   100   ND 
  - 5       2    0    0    N D  
  -5(q)     1   0   0   ND 
  -7      13   0   0   0.005 
  -7(q)     7   0   0   ND 
  3q      5   1   20   ND 
  t(6;9)     4   0   0   ND 
  t(9;22)     2   1   50   ND 
  t(11q23)     16   1   6   0.014 
  complex  (>3  abnormalities)   11   0   0   0.018 
  other     55   10   18   0.004 
  normal        116    74    64               <0.001 
  ND    10   6   60    
 
Molecular  abnormalities       
  FLT3 ITD        78    47    60               <0.001 
  FLT3  TKD     32   14   44   0.243 
 N-RAS     25   3   12   0.024 
 K-RAS     8   5   63   0.130 
  CEBPA     17   0   0   0.001 
 
*All patients with a specific abnormality were considered, irrespective of the presence of additional 
abnormalities. P-values were calculated using Fisher’s exact test (two-tailed, ND = not determined).
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Table 3. NPM1 mutation-associated gene expression in 275 patients with de novo AML. The Top-50 unique most discriminating genes and 
fold change in expression with regard to NPM1 mutation as determined by SAM (up: increased expression in NPM1 mutant cases; down: 
decreased expression in NPM1 mutant cases). 
 
Upregulated in AML with mutant NPM1  Downregulated in AML with mutant NPM1 
Probe set id  Gene symbol    Fold change  Probe set id    Gene symbol  Fold change 
213844_at HOXA5    4.2   209543_s_at   CD34  -5.4 
205366_s_at HOXB6    2.6    206896_s_at    GNG7  -1.7 
208414_s_at HOXB3    1.8    209583_s_at    MOX2  -3.1 
204082_at PBX3    2.8   200953_s_at   CCND2  -2.1 
205600_x_at HOXB5    2.1    221004_s_at    ITM2C  -3.0 
206289_at HOXA4    2.1   205330_at   MN1  -4.3 
205453_at HOXB2    2.1   200602_at   APP  -2.6 
213150_at HOXA10    2.6   200665_s_at   SPARC  -3.8 
204069_at MEIS1   2.6   201015_s_at   JUP  -3.1 
209905_at HOXA9    2.8   218899_s_at   BAALC  -4.3 
201664_at SMC4L1    2.1   209679_s_at   LOC57228 -1.9 
209439_s_at PHKA2    1.6    219694_at    FLJ11127  -2.1 
206847_s_at HOXA7    1.5    206042_x_at    SNRPN  -2.5 
63825_at ABHD2    1.6    211535_s_at    FGFR1  -2.6 
219304_s_at PDGFD    1.9    214582_at    PDE3B  -1.8 
212820_at RC3    2.4   221523_s_at   RRAGD  -1.8 
213110_s_at COL4A5   2.9    213618_at    CENTD1  -1.7 
207111_at EMR1   2.1   218589_at   P2RY5  -3.3 
208557_at HOXA6    1.6   202016_at   MEST  -2.9 
203471_s_at PLEK    1.6    208116_s_at    MAN1A1  -3.1 
203680_at PRKAR2B    2.3   205240_at   GPSM2  -1.9 
202729_s_at LTBP1    3.6      202747_s_at  ITM2A  -4.1 
210145_at PLA2G4A    1.6   206622_at  TRH  -9.1 
220162_s_at CARD9    1.5    206726_at  PGDS  -4.7 
206298_at ARHGAP22    2.0 
219602_s_at FAM38B   1.9 
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Table 4.  NPM1 mutation prediction by using PAM.  
 
    10-fold CV error (n=184)   Error validation set (n=91) 
Predicted genotype  WT  mutant     WT  mutant     
Genotype 
WT NPM1 98  24      48  10   
mutant NPM1 0  62      0  33    
 
Most optimal result for NPM1 mutation prediction using a cohort of 275 cases of AML divided in a 
training and test set 
21. The number of probe sets used in this prediction was 22, which represent 
18 unique genes.  
10-fold CV error: 10-fold cross validation prediction error on training set (n=184), Error validation 
set: prediction error on validation set (n=91). 10-Fold cross validation works as follows: the model 
is fitted on 90% of the samples and the class of the remaining 10% is predicted. This procedure is 
repeated 10 times, with each part playing the role of the test samples and the error of all 10 parts 
added together to compute the overall error. The error within the validation set reflects the 
number of samples wrongfully predicted in this set. 
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Table 5: Univariable and multivariable analyses of NPM1 mutation as prognostic factor for event-free survival (EFS), disease-free 
survival (DFS) and overall survival (OS) in AML. 
   E F S       D F S       O S  
   HR  (95%  CI)   P
5    HR (95% CI)    P
5    HR (95% CI)    P
5 
Univariable 
Intermediate
1   2.06  (1.33-3.20)   1.3e-03   2.82  (1.63-4.87)   2.1e-04   2.67  (1.62-4.41)   1.2e-04 
Poor
1    3.88  (2.29-6.56)   4.3e-07   5.09  (2.61-9.91)   1.7e-06   4.44  (2.49-7.93)   4.5e-07  
WBC
2    1.14  (0.84-1.53)   3.9e-01   1.18  (0.84-1.68)   3.4e-01   1.19  (0.87-1.62)   2.9e-01 
Age  [decades]   1.05  (0.94-1.19)   3.8e-01   1.06  (0.92-1.22)   4.1e-01   1.17  (1.03-1.32)   1.4e-02 
FLT3 ITD
3   1.76  (1.28-2.41)   4.6e-04   1.71  (1.17-2.50)   5.6e-03   1.89  (1.36-2.62)   1.6e-04 
NPM1 mutation
4  0.88  (0.64-1.21)   4.3e-01   0.93  (0.64-1.34)   6.9e-01   0.90  (0.65-1.27)   5.7e-01 
 
Multivariable 
Intermediate
1   2.18  (1.36-3.50)   1.2e-03   3.11  (1.74-5.55)   1.3e-04   2.87  (1.69-4.86)   9.4e-05 
Poor
1    3.96  (2.34-6.74)   3.3e-07   5.73 (2.93-11.22)  3.5e-07   4.68  (2.60-8.43)   2.7e-07  
WBC
2    1.06  (0.78-1.44)   7.2e-01   1.10  (0.77-1.58)   6.0e-01   1.18  (0.85-1.63)   3.2e-01 
Age  [decades]   1.07  (0.95-1.21)   2.7e-01   1.10  (0.95-1.27)   2.1e-01   1.19  (1.05-1.35)   8.1e-03 
FLT3 ITD
3   1.96  (1.39-2.76)   1.2e-04   2.00  (1.31-3.06)   1.3e-03   2.13  (1.49-3.05)   3.3e-05 
NPM1 mutation
4 0.59  (0.41-0.85)    5.2e-03   0.52  (0.34-0.80)   3.1e-03   0.49  (0.33-0.72)   3.3e-04 
 
1 cytogenetic risk versus cytogenetic good risk 
2 >20e-09 versus <20e-09 WBC/l 
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